
Sol-Gel Technologies Ltd. — Investor Relations & Filings
Sol-Gel Technologies Ltd. is a dermatology company that develops and commercializes topical treatments for skin conditions. The company leverages a proprietary, silica-based microencapsulation technology to stabilize active ingredients and enable controlled drug delivery. Its portfolio includes commercialized products for acne vulgaris and rosacea. The development pipeline focuses on addressing unmet needs in rare dermatological diseases, with a lead candidate, patidegib gel, for the prevention of new basal cell carcinoma lesions in patients with Gorlin syndrome. Other therapeutic areas of interest include pachyonychia congenita and hyperkeratosis-related indications. The company's strategy involves identifying and developing promising dermatological assets to provide innovative formulations for patients.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 6-K | 2026-05-28 | English | |
| 6-K - Sol-Gel Technologies Ltd. (0001684693) (Filer) | 2026-03-24 | English | |
| 424B5 - Sol-Gel Technologies Ltd. (0001684693) (Filer) | 2026-03-24 | English | |
| EFFECT - Sol-Gel Technologies Ltd. (0001684693) (Filer) | 2026-03-24 | English | |
| SCHEDULE 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject) | 2026-03-23 | English | |
| POS AM - Sol-Gel Technologies Ltd. (0001684693) (Filer) | 2026-03-19 | English |
Browse filings by year
11 yearsMarket data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
ARGENT BIOPHARMA LIMITED
Develops plant-inspired and synthetic medicines for neurolo…
|
RGT | AU | Manufacturing |
|
argenx SE
Develops and commercializes antibody-based therapies for se…
|
1AE | NL | Manufacturing |
|
Armata Pharmaceuticals, Inc.
Develops bacteriophage therapeutics for antibiotic-resistan…
|
ARMP | US | Manufacturing |
|
AroCell AB
Develops and markets in vitro diagnostic (IVD) tests for on…
|
AROC | SE | Manufacturing |
|
ArriVent BioPharma, Inc.
Clinical-stage biopharma developing oncology drugs for diff…
|
AVBP | US | Manufacturing |
|
ARROWHEAD PHARMACEUTICALS, INC.
Biotechnology company developing RNAi therapies to treat in…
|
ARWR | US | Manufacturing |
|
ARS Pharmaceuticals, Inc.
Develops and commercializes needle-free products for admini…
|
SPRY | US | Manufacturing |
|
ARTELO BIOSCIENCES, INC.
Clinical-stage biopharma developing therapeutics by modulat…
|
ARTL | US | Manufacturing |
|
Arura Pharma Inc
Diversified manufacturer and distributor in consumer goods …
|
— | CA | Manufacturing |
|
Ascelia Pharma
Biotechnology company developing and commercializing novel …
|
ACE | SE | Manufacturing |
Sol-Gel Technologies Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34322/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34322 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34322 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34322 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34322}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Sol-Gel Technologies Ltd. (id: 34322)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.